Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer.
Cancers (Basel)
; 13(16)2021 Aug 19.
Article
in En
| MEDLINE
| ID: mdl-34439322
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
Cancers (Basel)
Year:
2021
Document type:
Article
Affiliation country:
Country of publication: